Vertex acquires Semma Therapeutics for $950M to develop diabetes cure
Category: #health  By Pankaj Singh  Date: 2019-09-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vertex acquires Semma Therapeutics for $950M to develop diabetes cure
  • The acquisition for $950 million has been an all-cash deal.
     
  • The strategic acquisition is expected to align itself perfectly with Vertex’s aim to create revolutionary medicines.

Vertex Pharmaceuticals, a biopharmaceutical company based in Massachusetts, is acquiring Semma Therapeutics with its stem cell-based treatments for diabetes for $950 million which is slated to wind up in the fourth quarter.

Semma was founded by Douglas Melton, a Ph.D., in the year 2014 to work on a possible cure for Type 1 diabetes. The idea has been to turn the undifferentiated pluripotent stem cells into pancreatic beta cells that produce insulin and are capable of being transplanted into patients. The company later launched itself with an investment of $44 million in the Series A round along with a partnership with Novartis, that the company chose over other suitors focused on diabetes for its expertise in cell therapy.

Apparently, Semma raised a massive $114 million in the Series B round in 2017 as well as hired Bastiano Sanna as its CEO. Sanna had been Novartis’ global head of the programs associated with stem cell transplant. Vertex is currently counting on the treatment that is capable of replacing the daily injections along with chronic care that comprises as a treatment for people suffering from Type 1 diabetes.

Vertex’s CEO, Jeffery Leiden M.D., Ph.D., who is expected to pass on his position to Reshma Kewalramani, company Chief Medical Officer, next year in April, stated that the acquisition will align perfectly with the company’s strategy of making investments in scientific innovation that would create revolutionary medicines for people who are suffering from critical diseases in specialty markets.

Apparently, Semma has two-pronged approaches for treating diabetes. The first approach will require a direct transplant of pancreatic cells into the patient’s liver, so that will help in the production of insulin to control the levels of blood sugar. The second approach comprises a device which protects and delivers the transplanted cells from the immune system of the patient.

 

Source Credit- https://www.fiercebiotech.com/biotech/vertex-plunks-down-950m-for-stem-cell-player-semma-therapeutics



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...